The Evolution of Ovarian Carcinoma Subclassification

The phenotypically informed histotype classification remains the mainstay of ovarian carcinoma subclassification. Histotypes of ovarian epithelial neoplasms have evolved with each edition of the WHO Classification of Female Genital Tumours. The current fifth edition (2020) lists five principal histo...

Full description

Bibliographic Details
Main Authors: Martin Köbel, Eun Young Kang
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/2/416
_version_ 1797495306699407360
author Martin Köbel
Eun Young Kang
author_facet Martin Köbel
Eun Young Kang
author_sort Martin Köbel
collection DOAJ
description The phenotypically informed histotype classification remains the mainstay of ovarian carcinoma subclassification. Histotypes of ovarian epithelial neoplasms have evolved with each edition of the WHO Classification of Female Genital Tumours. The current fifth edition (2020) lists five principal histotypes: high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), mucinous carcinoma (MC), endometrioid carcinoma (EC) and clear cell carcinoma (CCC). Since histotypes arise from different cells of origin, cell lineage-specific diagnostic immunohistochemical markers and histotype-specific oncogenic alterations can confirm the morphological diagnosis. A four-marker immunohistochemical panel (WT1/p53/napsin A/PR) can distinguish the five principal histotypes with high accuracy, and additional immunohistochemical markers can be used depending on the diagnostic considerations. Histotypes are further stratified into molecular subtypes and assessed with predictive biomarker tests. HGSCs have recently been subclassified based on mechanisms of chromosomal instability, mRNA expression profiles or individual candidate biomarkers. ECs are composed of the same molecular subtypes (<i>POLE</i>-mutated/mismatch repair-deficient/no specific molecular profile/p53-abnormal) with the same prognostic stratification as their endometrial counterparts. Although methylation analyses and gene expression and sequencing showed at least two clusters, the molecular subtypes of CCCs remain largely elusive to date. Mutational and immunohistochemical data on LGSC have suggested five molecular subtypes with prognostic differences. While our understanding of the molecular composition of ovarian carcinomas has significantly advanced and continues to evolve, the need for treatment options suitable for these alterations is becoming more obvious. Further preclinical studies using histotype-defined and molecular subtype-characterized model systems are needed to expand the therapeutic spectrum for women diagnosed with ovarian carcinomas.
first_indexed 2024-03-10T01:46:01Z
format Article
id doaj.art-2fa39546142c43c8a6efcbbb3f2e7597
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-10T01:46:01Z
publishDate 2022-01-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-2fa39546142c43c8a6efcbbb3f2e75972023-11-23T13:14:37ZengMDPI AGCancers2072-66942022-01-0114241610.3390/cancers14020416The Evolution of Ovarian Carcinoma SubclassificationMartin Köbel0Eun Young Kang1Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB T2N 2T9, CanadaDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB T2N 2T9, CanadaThe phenotypically informed histotype classification remains the mainstay of ovarian carcinoma subclassification. Histotypes of ovarian epithelial neoplasms have evolved with each edition of the WHO Classification of Female Genital Tumours. The current fifth edition (2020) lists five principal histotypes: high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), mucinous carcinoma (MC), endometrioid carcinoma (EC) and clear cell carcinoma (CCC). Since histotypes arise from different cells of origin, cell lineage-specific diagnostic immunohistochemical markers and histotype-specific oncogenic alterations can confirm the morphological diagnosis. A four-marker immunohistochemical panel (WT1/p53/napsin A/PR) can distinguish the five principal histotypes with high accuracy, and additional immunohistochemical markers can be used depending on the diagnostic considerations. Histotypes are further stratified into molecular subtypes and assessed with predictive biomarker tests. HGSCs have recently been subclassified based on mechanisms of chromosomal instability, mRNA expression profiles or individual candidate biomarkers. ECs are composed of the same molecular subtypes (<i>POLE</i>-mutated/mismatch repair-deficient/no specific molecular profile/p53-abnormal) with the same prognostic stratification as their endometrial counterparts. Although methylation analyses and gene expression and sequencing showed at least two clusters, the molecular subtypes of CCCs remain largely elusive to date. Mutational and immunohistochemical data on LGSC have suggested five molecular subtypes with prognostic differences. While our understanding of the molecular composition of ovarian carcinomas has significantly advanced and continues to evolve, the need for treatment options suitable for these alterations is becoming more obvious. Further preclinical studies using histotype-defined and molecular subtype-characterized model systems are needed to expand the therapeutic spectrum for women diagnosed with ovarian carcinomas.https://www.mdpi.com/2072-6694/14/2/416ovarian cancersubclassificationhistotypemolecular subtypeimmunohistochemistry
spellingShingle Martin Köbel
Eun Young Kang
The Evolution of Ovarian Carcinoma Subclassification
Cancers
ovarian cancer
subclassification
histotype
molecular subtype
immunohistochemistry
title The Evolution of Ovarian Carcinoma Subclassification
title_full The Evolution of Ovarian Carcinoma Subclassification
title_fullStr The Evolution of Ovarian Carcinoma Subclassification
title_full_unstemmed The Evolution of Ovarian Carcinoma Subclassification
title_short The Evolution of Ovarian Carcinoma Subclassification
title_sort evolution of ovarian carcinoma subclassification
topic ovarian cancer
subclassification
histotype
molecular subtype
immunohistochemistry
url https://www.mdpi.com/2072-6694/14/2/416
work_keys_str_mv AT martinkobel theevolutionofovariancarcinomasubclassification
AT eunyoungkang theevolutionofovariancarcinomasubclassification
AT martinkobel evolutionofovariancarcinomasubclassification
AT eunyoungkang evolutionofovariancarcinomasubclassification